Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder.

Cerou M, Peigné S, Comets E, Chenel M.

AAPS J. 2019 Nov 12;22(1):4. doi: 10.1208/s12248-019-0379-x.

PMID:
31720897
2.

Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and Development.

Gupta N, Bottino D, Simonsson USH, Musante CJ, Bueters T, Rieger TR, Macha S, Chenel M, Fancourt C, Kanodia J, Nayak S.

Clin Pharmacol Ther. 2019 Nov 10. doi: 10.1002/cpt.1667. [Epub ahead of print] No abstract available.

PMID:
31709519
3.

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.

Pierrillas PB, Henin E, Ball K, Ogier J, Amiel M, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

Drug Metab Dispos. 2019 Jun;47(6):648-656. doi: 10.1124/dmd.118.085605. Epub 2019 Apr 2.

PMID:
30940629
4.

Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice.

Pierrillas PB, Henin E, Ogier J, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

J Pharmacol Exp Ther. 2018 Dec;367(3):414-424. doi: 10.1124/jpet.118.251694. Epub 2018 Sep 18.

PMID:
30228112
5.

Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Pierrillas PB, Fouliard S, Chenel M, Hooker AC, Friberg LE, Karlsson MO.

AAPS J. 2018 Mar 27;20(3):55. doi: 10.1208/s12248-018-0218-5.

PMID:
29589158
6.

Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Pierrillas PB, Fouliard S, Chenel M, Hooker AC, Friberg LE, Karlsson MO.

AAPS J. 2018 Mar 7;20(2):39. doi: 10.1208/s12248-018-0206-9. Erratum in: AAPS J. 2018 Mar 27;20(3):55.

PMID:
29516207
7.

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity.

Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE.

Clin Cancer Res. 2018 Jun 1;24(11):2631-2641. doi: 10.1158/1078-0432.CCR-17-2265. Epub 2018 Feb 20.

8.

Development and performance of npde for the evaluation of time-to-event models.

Cerou M, Lavielle M, Brendel K, Chenel M, Comets E.

Pharm Res. 2018 Jan 9;35(2):30. doi: 10.1007/s11095-017-2291-3.

PMID:
29368033
9.

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use.

Nayak S, Sander O, Al-Huniti N, de Alwis D, Chain A, Chenel M, Sunkaraneni S, Agrawal S, Gupta N, Visser SAG.

Clin Pharmacol Ther. 2018 Mar;103(3):378-383. doi: 10.1002/cpt.978. Epub 2018 Jan 13. Erratum in: Clin Pharmacol Ther. 2018 Nov;104(5):1031.

10.

Model Description Language (MDL): A Standard for Modeling and Simulation.

Smith MK, Moodie SL, Bizzotto R, Blaudez E, Borella E, Carrara L, Chan P, Chenel M, Comets E, Gieschke R, Harling K, Harnisch L, Hartung N, Hooker AC, Karlsson MO, Kaye R, Kloft C, Kokash N, Lavielle M, Lestini G, Magni P, Mari A, Mentré F, Muselle C, Nordgren R, Nyberg HB, Parra-Guillén ZP, Pasotti L, Rode-Kristensen N, Sardu ML, Smith GR, Swat MJ, Terranova N, Yngman G, Yvon F, Holford N; DDMoRe consortium.

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):647-650. doi: 10.1002/psp4.12222. Epub 2017 Jul 12. No abstract available.

11.

Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling.

Ball K, Jamier T, Parmentier Y, Denizot C, Mallier A, Chenel M.

Eur J Pharm Sci. 2017 Aug 30;106:122-132. doi: 10.1016/j.ejps.2017.05.055. Epub 2017 May 25.

PMID:
28552429
12.

Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor Sizes.

Pierrillas PB, Tod M, Amiel M, Chenel M, Henin E.

AAPS J. 2016 Sep;18(5):1262-1272. doi: 10.1208/s12248-016-9936-8. Epub 2016 Jun 21.

PMID:
27329303
13.

Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.

Tessier A, Bertrand J, Chenel M, Comets E.

CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):123-31. doi: 10.1002/psp4.12054. Epub 2016 Mar 14.

14.

Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

EFPIA MID3 Workgroup, Marshall SF, Burghaus R, Cosson V, Cheung SY, Chenel M, DellaPasqua O, Frey N, Hamrén B, Harnisch L, Ivanow F, Kerbusch T, Lippert J, Milligan PA, Rohou S, Staab A, Steimer JL, Tornøe C, Visser SA.

CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122. doi: 10.1002/psp4.12049. Epub 2016 Mar 14.

15.

Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller Tumors.

Pierrillas PB, Tod M, Amiel M, Chenel M, Henin E.

AAPS J. 2016 Mar;18(2):404-15. doi: 10.1208/s12248-015-9862-1. Epub 2016 Jan 12.

16.

Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.

Peigné S, Fouliard S, Decourcelle S, Chenel M.

J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):29-43. doi: 10.1007/s10928-015-9452-y. Epub 2015 Nov 14.

PMID:
26578442
17.

Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.

Peigné S, Bouzom F, Brendel K, Gesson C, Fouliard S, Chenel M.

J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):13-27. doi: 10.1007/s10928-015-9451-z. Epub 2015 Nov 12.

PMID:
26563503
18.

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development.

Swat MJ, Moodie S, Wimalaratne SM, Kristensen NR, Lavielle M, Mari A, Magni P, Smith MK, Bizzotto R, Pasotti L, Mezzalana E, Comets E, Sarr C, Terranova N, Blaudez E, Chan P, Chard J, Chatel K, Chenel M, Edwards D, Franklin C, Giorgino T, Glont M, Girard P, Grenon P, Harling K, Hooker AC, Kaye R, Keizer R, Kloft C, Kok JN, Kokash N, Laibe C, Laveille C, Lestini G, Mentré F, Munafo A, Nordgren R, Nyberg HB, Parra-Guillen ZP, Plan E, Ribba B, Smith G, Trocóniz IF, Yvon F, Milligan PA, Harnisch L, Karlsson M, Hermjakob H, Le Novère N.

CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):316-9. doi: 10.1002/psp4.57. Epub 2015 Jun 15.

19.

Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates.

Tessier A, Bertrand J, Chenel M, Comets E.

AAPS J. 2015 May;17(3):597-608. doi: 10.1208/s12248-015-9726-8. Epub 2015 Feb 20.

20.

Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.

Chalret du Rieu Q, Fouliard S, White-Koning M, Kloos I, Chatelut E, Chenel M.

Invest New Drugs. 2014 Oct;32(5):985-94. doi: 10.1007/s10637-014-0118-1. Epub 2014 May 31.

PMID:
24875134
21.

Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.

Dumont C, Chenel M, Mentré F.

J Biopharm Stat. 2014;24(3):471-92. doi: 10.1080/10543406.2014.888443.

22.

Development of a physiologically-based pharmacokinetic model of the rat central nervous system.

Badhan RK, Chenel M, Penny JI.

Pharmaceutics. 2014 Mar 18;6(1):97-136. doi: 10.3390/pharmaceutics6010097.

23.

Influence of the duration of intravenous drug administration on tumor uptake.

Fouliard S, Chenel M, Marcucci F.

Front Oncol. 2013 Jul 25;3:192. doi: 10.3389/fonc.2013.00192. eCollection 2013.

24.

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.

Mentré F, Chenel M, Comets E, Grevel J, Hooker A, Karlsson MO, Lavielle M, Gueorguieva I.

CPT Pharmacometrics Syst Pharmacol. 2013 Jun 5;2:e46. doi: 10.1038/psp.2013.19. No abstract available.

25.

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.

Fouliard S, Robert R, Jacquet-Bescond A, du Rieu QC, Balasubramanian S, Loury D, Loriot Y, Hollebecque A, Kloos I, Soria JC, Chenel M, Depil S.

Eur J Cancer. 2013 Sep;49(13):2791-7. doi: 10.1016/j.ejca.2013.05.009. Epub 2013 Jun 18.

PMID:
23790467
26.

Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.

Chalret du Rieu Q, Fouliard S, Jacquet-Bescond A, Robert R, Kloos I, Depil S, Chatelut E, Chenel M.

Pharm Res. 2013 Oct;30(10):2640-53. doi: 10.1007/s11095-013-1089-1. Epub 2013 Jun 5.

PMID:
23737346
27.

A physiologically based pharmacokinetic model for strontium exposure in rat.

Pertinez H, Chenel M, Aarons L.

Pharm Res. 2013 Jun;30(6):1536-52. doi: 10.1007/s11095-013-0991-x. Epub 2013 Mar 30.

PMID:
23543304
28.

Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.

Dumont C, Mentré F, Gaynor C, Brendel K, Gesson C, Chenel M.

Clin Pharmacokinet. 2013 Jan;52(1):43-57. doi: 10.1007/s40262-012-0022-9.

29.

Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models.

Bertrand J, Comets E, Chenel M, Mentré F.

Biometrics. 2012 Mar;68(1):146-55. doi: 10.1111/j.1541-0420.2011.01665.x. Epub 2011 Nov 3.

30.

Development of a complex parent-metabolite joint population pharmacokinetic model.

Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E.

AAPS J. 2011 Sep;13(3):390-404. doi: 10.1208/s12248-011-9282-9. Epub 2011 May 27.

31.

Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.

Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, Bouzom F.

Clin Pharmacokinet. 2010 Apr;49(4):239-58. doi: 10.2165/11318130-000000000-00000.

PMID:
20214408
32.

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Bertrand J, Comets E, Laffont CM, Chenel M, Mentré F.

J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):317-39. doi: 10.1007/s10928-009-9124-x. Epub 2009 Jun 27.

33.

Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.

Chenel M, Bouzom F, Aarons L, Ogungbenro K.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):635-59. doi: 10.1007/s10928-008-9104-6. Epub 2009 Jan 7.

PMID:
19130188
34.

Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.

Chenel M, Bouzom F, Cazade F, Ogungbenro K, Aarons L, Mentré F.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):661-81. doi: 10.1007/s10928-008-9105-5. Epub 2009 Jan 7.

35.

Norfloxacin blood-brain barrier transport in rats is not affected by probenecid coadministration.

Marchand S, Forsell A, Chenel M, Comets E, Lamarche I, Couet W.

Antimicrob Agents Chemother. 2006 Jan;50(1):371-3.

36.

Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.

Chenel M, Ogungbenro K, Duval V, Laveille C, Jochemsen R, Aarons L.

J Pharmacokinet Pharmacodyn. 2005 Dec;32(5-6):737-56.

PMID:
16341474
37.

Pharmacokinetic modeling of free amoxicillin concentrations in rat muscle extracellular fluids determined by microdialysis.

Marchand S, Chenel M, Lamarche I, Couet W.

Antimicrob Agents Chemother. 2005 Sep;49(9):3702-6.

38.
39.

Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats.

Marchand S, Chenel M, Lamarche I, Pariat C, Couet W.

J Pharm Sci. 2003 Dec;92(12):2458-65.

PMID:
14603491
40.

Norfloxacin-induced electroencephalogram alteration and seizures in rats are not triggered by enhanced levels of intracerebral glutamate.

Chenel M, Limosin A, Marchand S, Paquereau J, Mimoz O, Couet W.

Antimicrob Agents Chemother. 2003 Nov;47(11):3660-2.

41.

Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats.

Chenel M, Barbot A, Dupuis A, Mimoz O, Paquereau J, Bouquet S, Couet W.

Antimicrob Agents Chemother. 2003 Jun;47(6):1952-7.

Supplemental Content

Loading ...
Support Center